Patents Examined by Patrick Lewis
  • Tricyclic nucleosides and oligomeric compounds prepared therefrom
    Patent number: 9249178
    Abstract: The present invention provides novel tricyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the tricyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of the oligomeric compound. Such oligomeric compounds can also be included in double stranded compositions. In certain embodiments, the oligomeric compounds provided herein are expected to hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 2, 2016
    Inventors: Christian Leumann, Branislav Dugovic, Jory Liétard
  • Compounds and pharmaceutical compositions for the treatment of viral infections
    Patent number: 9243025
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: January 26, 2016
    Assignee: Idenix Pharmaceuticals, LLC
    Inventors: Dominique Surleraux, Gilles Gosselin
  • Purification of synthetic oligonucleotides
    Patent number: 9243023
    Abstract: This invention provides a method for purifying synthetic oligonucleotides comprising capping, polymerizing and separating any failure sequences produced during oligonucleotide synthesis. The invention also provides a method for purifying synthetic oligonucleotides comprising reacting a full length oligonucleotide with a compound to attach a polymerizable functional group to an end of the full length oligonucleotide, polymerizing the full length oligonucleotides and removing the failure sequences, and recovering the full length oligonucleotides. The invention also provides novel capping agents having a polymerizable functional group, and kits comprising at least one composition of the present invention.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: January 26, 2016
    Assignee: MICHIGAN TECHNOLOGICAL UNIVERSITY
    Inventor: Shiyue Fang
  • Compositions containing resveratrol and nucleotides
    Patent number: 9226937
    Abstract: A resveratrol-containing composition capable of providing a therapeutic benefit to a subject such as modulation of a biological activity, improving cell transplantation therapy, or improving macular degeneration or dystrophy treatments. The compositions comprise trans-resveratrol, a metal chelator, one or more additional antioxidants such as quercetin, gamma-tocotrienol, or apple polyphenols, allicin, and nucleotides.
    Type: Grant
    Filed: November 24, 2014
    Date of Patent: January 5, 2016
    Assignee: RESVERATROL PARTNERS, LLC
    Inventor: William F. Sardi
  • Extraction buffer and method for isolating high-quality RNA from cells exposed to metal chloride solutions and clay mineral suspensions
    Patent number: 9200272
    Abstract: An RNA extraction buffer, an RNA extraction method, and an RNA extraction kit are described which enable functional, rapid, efficient, and high-quality RNA isolation from samples containing high concentrations of aqueous metal cations, clays, silica, or silicate minerals.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: December 1, 2015
    Assignee: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Andrea Loes, Shelley Haydel
  • Process for the preparation of certain triaryl rhamnose carbamates
    Patent number: 9193750
    Abstract: Triaryl rhamnose carbamate insecticides are prepared from triaryl acyl azides and tetrahydropyran-2-ols in good yield without the use of a hydride base.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: November 24, 2015
    Assignee: Dow AgroSciences LC
    Inventors: Lawrence C. Creemer, Carl DeAmicis, Gary D. Crouse, Peter Borromeo
  • Chitosan stenting paste
    Patent number: 9192692
    Abstract: Nasal or sinus site may be treated with a ready-to-use paste having a high concentration of a water-soluble chitosan, an osmolality reducing agent in a phosphate-containing solution. The paste forms at room temperature, has a pH of at least 4 and the osmolality reducing agent does not crosslink with the water-soluble chitosan. The paste provides stenting and adheres to the nasal or sinus site and has a residence time of at least 1 day.
    Type: Grant
    Filed: October 24, 2013
    Date of Patent: November 24, 2015
    Assignee: Medtronic Xomed, INc.
    Inventors: Jennifer Gates Medina, Ethan Glenn Sherman
  • Chitosan paste wound dressing
    Patent number: 9192574
    Abstract: A method for treating a wound with a ready-to-use composition having a high concentration of a water-soluble chitosan in a phosphate-containing solution. The composition is a paste at room temperature, has a pH of at least 4, adheres to the body tissue or surgical site and has a residence time of at least 1 day.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: November 24, 2015
    Assignee: Medtronic Xomed, Inc.
    Inventors: Jennifer Gates Medina, Ethan Glenn Sherman
  • Compounds and compositions for the treatment of parasitic diseases
    Patent number: 9186361
    Abstract: The present invention provides compounds of Formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as Leishmaniasis, Human African Trypanosomiasis and Chagas disease.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: November 17, 2015
    Assignee: Novartis AG
    Inventors: Arnab Kumar Chatterjee, Fang Liang, Casey Jacob Nelson Mathison, Pranab Kumar Mishra, Valentina Molteni, Advait Suresh Nagle, Frantisek Supek, Liying Jocelyn Tan, Agnes Vidal
  • Cellulose resin and process for producing the same
    Patent number: 9181351
    Abstract: A cellulose resin produced by binding cellulose or a derivative thereof and cardanol or a derivative thereof by using a hydroxy group of the cellulose or a derivative thereof and a hydroxy group of the cardanol or a derivative thereof, in which carbon atoms to which the hydroxy groups are bound are mutually linked via a carbonate bond or urethane bond formed by using the hydroxy groups.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: November 10, 2015
    Assignee: NEC CORPORATION
    Inventors: Shukichi Tanaka, Sungil Moon, Masatoshi Iji
  • Nucleoside analogues for the treatment of a viral infection, and method for evaluating the sensitivity to said treatment
    Patent number: 9181294
    Abstract: The present invention describes the use of nucleoside analogs for the treatment of viral infections, in particular of an HIV infection, and also compositions comprising at least one of these analogs, and a method for evaluating the sensitivity to said treatment.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: November 10, 2015
    Assignee: Universite Pierre Et Marie Curie (Paris 6)
    Inventors: Vincent Calvez, Anne-Genevieve Marcelin, Cathia Soulie, Melanie Etheve-Quelquejeu, Matthieu Sollogoub
  • Compounds, compositions, and methods for preventing metastasis of cancer cells
    Patent number: 9174950
    Abstract: Disclosed are methods for preventing metastasis of cancer cells. The disclosed compounds can be used to prevent the spread of tumor or other types of cancer cells.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: November 3, 2015
    Assignee: Aerpio Therapeutics, Inc.
    Inventors: Robert Shalwitz, Kevin Gene Peters
  • Methods of synthesizing substituted purine compounds
    Patent number: 9175032
    Abstract: The present invention provides an efficient process for the synthesis of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT1-mediated protein methylation plays a part, such as cancer and neurological disorders, by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also provides novel crystalline forms of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof (Form A, Form B, and Form C), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 3, 2015
    Assignee: Epizyme, Inc.
    Inventor: Edward James Olhava
  • Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
    Patent number: 9173893
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: November 3, 2015
    Assignee: Cocrystal Pharma, Inc.
    Inventors: Jong Hyun Cho, Steven J. Coats, Raymond F. Schinazi, Hongwang Zhang, Longhu Zhou
  • Artificial nucleic acids
    Patent number: 9169256
    Abstract: Artificial nucleosides including 2-methyl-nucleobase-substituted butane-1,3-diol nucleosides are disclosed. Four different stereoisomers of such nucleosides are possible. Oligonucleotides made up of the artificial nucleosides form homoduplexes of greater stability than DNA duplexes and have a reduced ability to hybridize to DNA or RNA.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: October 27, 2015
    Assignee: ELITechGroup B.V.
    Inventors: Noah Scarr, Eugeny A. Lukhtanov
  • Methods for treating glaucoma using uridine diphosphate derivatives
    Patent number: 9163055
    Abstract: This disclosure relates to prodrugs of uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: October 20, 2015
    Assignee: TUFTS UNIVERSITY
    Inventors: Philip G. Haydon, Jinbo Lee
  • Natural sweetener
    Patent number: 9161562
    Abstract: The invention relates to extracts, in particular non-nutrient phytochemicals, form sugar cane or sugar beet waste products, such as molasses, sugar mud and bagasse, which have Glycemic Index (GI) lowering properties and their use as sweeteners and in foods containing sugar.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: October 20, 2015
    Assignee: Horizon Science Pty Ltd
    Inventors: David Kannar, Barry James Kitchen
  • Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
    Patent number: 9156874
    Abstract: This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 13, 2015
    Assignee: Nanjing Molecular Research, Inc.
    Inventors: Junbiao Chang, Qiang Huang, Runcong Liu, Zheng Wang
  • Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
    Patent number: 9156875
    Abstract: Immunostimulatory oligoribonucleotides (ORN) featuring 5?-triphosphates and various 5?-triphosphate analogs are provided. Also provided are physiologically acceptable salts of the immunostimulatory ORN and pharmaceutical compositions containing the immunostimulatory ORN of the invention. ORN of the invention are useful as adjuvants and can be combined with an antigen to promote an antigen-specific immune response. ORN of the invention are also particularly useful for promoting a Th1-type immune response. Also provided are methods of use of the compounds and pharmaceutical compositions of the invention to enhance an immune response in a subject, as well to treat a number of conditions including cancer, infection, allergy, and asthma, and to vaccinate a subject against an antigen.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: October 13, 2015
    Assignee: AdiuTide Pharmaceuticals GmbH
    Inventors: Harald Debelak, Eugen Uhlmann
  • Neuro-protective compounds and their use
    Patent number: 9150608
    Abstract: Isolated compounds from Adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the Adelostemma gracillimum refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: October 6, 2015
    Assignee: Biotechnology Research Corp. Ltd.
    Inventors: Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Shengjun Guo